{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:55Z","timestamp":1793755075626,"version":"4.6.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40265-022-01734-y","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T06:04:17Z","timestamp":1655445857000},"page":"1017-1023","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Oteseconazole: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"1734_CR1","first-page":"CD009151","volume":"1","author":"G Cooke","year":"2022","unstructured":"Cooke G, Watson C, Deckx L, et al. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2022;1:CD009151.","journal-title":"Cochrane Database Syst Rev"},{"key":"1734_CR2","unstructured":"Mycovia Pharmaceuticals. FDA approves Mycovia Pharmaceuticals VIVJOA\u2122 (oteseconazole), the first and only FDA-approved medication for recurrent vulvovaginal candidiasis (chronic yeast infection) [media release]. 28 Apr 2022. https:\/\/mycovia.com\/."},{"key":"1734_CR3","unstructured":"Mycovia Pharmaceuticals. VIVJOA\u2122 (oteseconazole) capsules, for oral use. 2022. https:\/\/www.fda.gov\/. Accessed 29 Apr 2022."},{"key":"1734_CR4","unstructured":"Mycovia Pharmaceuticals, Jiangsu Hengrui Medicine. Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine announce partnership to develop and commercialize VT-1161 for recurrent vulvovaginal candidiasis and other fungal conditions [media release]. 17 Jun 2019. https:\/\/mycovia.com\/."},{"key":"1734_CR5","unstructured":"Mycovia Pharmaceuticals. Mycovia Pharmaceuticals announces partnership with Gedeon Richter to commercialize and manufacture VT-1161 for recurrent vulvovaginal candidiasis [media release]. 16 Oct 2019. https:\/\/mycovia.com\/."},{"issue":"12","key":"1734_CR6","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1128\/AAC.03707-14","volume":"58","author":"AG Warrilow","year":"2014","unstructured":"Warrilow AG, Hull CM, Parker JE, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014;58(12):7121\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"1734_CR7","doi-asserted-by":"publisher","first-page":"S459","DOI":"10.1093\/ofid\/ofab466.916","volume":"8","author":"M Ghannoum","year":"2021","unstructured":"Ghannoum M, Degenhardt T, Person K. Susceptibility testing of oteseconazole (VT-1161) against clinical isolates from phase 3 clinical studies in subjects with recurrent vulvovaginal candidiasis [abstract no. 719]. Open Forum Infect Dis. 2021;8(Suppl 1):S459.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1734_CR8","first-page":"918","volume":"113","author":"L Wang","year":"2021","unstructured":"Wang L, Zhang M, Guo J, et al. In vitro activities of the tetrazole VT-1161 compared with itraconazole and fluconazole against Cryptococcus and non-albicans Candida species. Mycologia. 2021;113(5):918\u201325.","journal-title":"Mycologia"},{"issue":"9","key":"1734_CR9","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1128\/AAC.00185-15","volume":"59","author":"EP Garvey","year":"2015","unstructured":"Garvey EP, Hoekstra WJ, Schotzinger RJ, et al. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015;59(9):5567\u201373.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1734_CR10","doi-asserted-by":"publisher","first-page":"e02114","DOI":"10.1128\/AAC.02114-18","volume":"63","author":"BC Monk","year":"2019","unstructured":"Monk BC, Keniya MV, Sabherwal M, et al. Azole resistance reduces susceptibility to the tetrazole antifungal VT-1161. Antimicrob Agents Chemother. 2019;63(1):e02114-e2118.","journal-title":"Antimicrob Agents Chemother"},{"key":"1734_CR11","first-page":"e00341","volume":"63","author":"AT Nishimoto","year":"2019","unstructured":"Nishimoto AT, Wiederhold NP, Flowers SA, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2019;63:e00341-e419.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1734_CR12","doi-asserted-by":"publisher","first-page":"e01817","DOI":"10.1128\/AAC.01817-16","volume":"61","author":"WA Schell","year":"2017","unstructured":"Schell WA, Jones AM, Garvey EP, et al. Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother. 2017;61(3):e01817-e1916.","journal-title":"Antimicrob Agents Chemother"},{"key":"1734_CR13","first-page":"e01304","volume":"63","author":"AT Nishimoto","year":"2019","unstructured":"Nishimoto AT, Whaley SG, Wiederhold NP, et al. Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. Antimicrob Agents Chemother. 2019;63:e01304-e1319.","journal-title":"Antimicrob Agents Chemother"},{"key":"1734_CR14","unstructured":"US FDA Center for Drug Evaluation and Research. Integrated review. 2022. https:\/\/www.fda.gov\/. Accessed 26 May 2022."},{"issue":"2","key":"1734_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ajog.2021.11.1279","volume":"226","author":"K Person","year":"2022","unstructured":"Person K, Brand S, Degenhardt T, et al. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oteseconazole (VT-1161) oral capsules in the treatment of subjects with recurrent vulvovaginal candidiasis (VIOLET) [abstract no. 5]. Am J Obstet Gynecol. 2022;226(2):292.","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 1","key":"1734_CR16","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1093\/ofid\/ofab466.107","volume":"8","author":"MG Martens","year":"2021","unstructured":"Martens MG, Maximos B, Degenhardt T, et al. A phase 3, randomized, double-blind study to evaluate the efficacy and safety of oteseconazole (VT-1161) oral capsules versus fluconazole and placebo in the treatment of acute vulvovaginal candidiasis episodes in subjects with recurrent vulvovaginal candidiasis (ultraVIOLET) [abstract no. 107]. Open Forum Infect Dis. 2021;8(Suppl 1):S66\u20137.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"1734_CR17","doi-asserted-by":"publisher","first-page":"624.e1-e9","DOI":"10.1016\/j.ajog.2018.03.001","volume":"218","author":"SR Brand","year":"2018","unstructured":"Brand SR, Degenhardt TP, Person K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018;218(6):624.e1-e9.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"1734_CR18","doi-asserted-by":"publisher","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","volume":"73","author":"SR Brand","year":"2021","unstructured":"Brand SR, Sobel JD, Nyirjesy P, et al. A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis. 2021;73(7):e1518\u201324.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1734_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bjd.19224","volume":"184","author":"B Elewski","year":"2021","unstructured":"Elewski B, Brand S, Degenhardt T, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. Br J Dermatol. 2021;184(2):270\u201380.","journal-title":"Br J Dermatol"},{"key":"1734_CR20","unstructured":"Mycovia Pharmaceuticals. Mycovia Pharmaceuticals initiates extension clinical studies to further evaluate long-term efficacy of oteseconazole (VT-1161) in patients with recurrent vulvovaginal candidiasis [media release]. 11 Feb 2020. http:\/\/www.mycovia.com."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01734-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01734-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01734-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T17:02:33Z","timestamp":1657645353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01734-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01734-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"17 June 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}